Pharmaceutical Compliance

Understanding GxP and Regulatory Compliance for Pharmaceutical Companies

A guide to managing GxP compliance, FDA submissions, and EMA regulatory requirements across global pharmaceutical markets.

Key regulations

GxP compliance

Good Manufacturing, Laboratory, Clinical, and Distribution Practices set the baseline for quality and safety in pharmaceutical operations, covering everything from production to clinical research.

FDA 21 CFR Part 11

The FDA's regulation on electronic records and electronic signatures establishes requirements for audit trails, access controls, and system validation in regulated environments.

EMA submissions

Regulatory submissions to the European Medicines Agency follow the eCTD format and require structured documentation, cross-referencing, and adherence to evolving guidance documents.

Pharmacovigilance

Pharmaceutical companies are required to systematically monitor adverse events, detect safety signals, and prepare periodic safety update reports throughout a product's lifecycle.

Key compliance challenges

•Tracking regulatory obligations across multiple GxP frameworks (GMP, GLP, GCP, GDP) with different requirements for each operational area.
•Maintaining audit-ready documentation for FDA, EMA, and other global regulatory authorities with varying submission formats and timelines.
•Managing the complexity of pharmacovigilance reporting, including adverse event detection, signal management, and periodic safety updates.
•Keeping electronic systems validated and compliant with 21 CFR Part 11 as technology and regulatory expectations evolve.

Want to stay informed?

Read our latest insights on pharmaceutical regulatory compliance.

Browse Pharma articles →